For patients, caregivers, loved ones and healthcare specialists
The people living with, supporting and treating those with genetically-defined cancers are at the center of what we do. Your contributions and feedback are important to the success of Aadi in finding safe and effective treatments. We are working diligently towards our goal of developing precision therapies for genetically-defined cancers.
We have engaged multiple advocacy and research groups across the sarcoma landscape in order to optimize the design of our clinical studies, increase study awareness in the community, and to enrich our understanding of the evolving precision oncology environment.
PRECISION 1 is the first prospective, tumor-agnostic trial of nab-sirolimus for patients who are mTOR inhibitor naive and with malignant solid tumors harboring inactivating alterations in TSC1 or TSC2 genes.
What is PRECISION 1?
PRECISION 1 is a prospective, phase 2, open-label, tumor-agnostic, multicenter basket trial of nab-sirolimus for patients aged 12 years or older with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes, which are tumor suppressor genes upstream in the mTOR pathway.
Enrolled patients (N=~120) will be allocated into 2 treatment arms:
Arm A (N=~60) includes patients with pathogenic inactivating TSC1 alterations
Arm B (N=~60) includes patients with pathogenic inactivating TSC2 alterations
The primary objective of the study is to determine the overall response rate (ORR) in patients harboring pathogenic inactivating alterations in TSC1 or TSC2 genes until disease progression.